Eli Lilly: olomorasib receives FDA Breakthrough Therapy for previously treated KRAS G12C advanced pancreatic cancer

Key highlights
  • FDA granted Breakthrough Therapy designation to olomorasib as monotherapy for adults with advanced pancreatic cancer and a KRAS G12C mutation after ≥1 prior systemic therapy.
  • Designation is based on preliminary results from the open‑label, multicenter Phase 1/2 LOXO‑RAS‑20001 study (NCT04956640).
  • Olomorasib is a next‑generation, potent and highly selective KRAS G12C inhibitor.
  • Olomorasib previously received Breakthrough Therapy designation in combination with pembrolizumab for first‑line KRAS G12C NSCLC with PD‑L1 ≥50%.

Regulatory decision

The U.S. FDA granted Breakthrough Therapy designation to olomorasib as a monotherapy for adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and whose tumors harbor a KRAS G12C mutation as determined by an FDA‑approved test. Breakthrough designation is intended to expedite development and review when preliminary clinical evidence indicates a drug may offer substantial improvement over available therapies.

Clinical evidence

The designation is based on encouraging preliminary results from the open‑label, multicenter Phase 1/2 LOXO‑RAS‑20001 study (NCT04956640) of olomorasib in patients with KRAS G12C‑mutant advanced solid tumors, including previously treated pancreatic cancer patients.

Disease context

Pancreatic cancer is diagnosed in about 60,000 people annually in the U.S., with roughly 50,000 projected deaths each year; metastatic disease has a five‑year survival rate under 5%. There are currently no approved therapies that specifically target KRAS G12C‑mutant pancreatic cancer.

Development programme

Olomorasib is described as a potent, highly selective next‑generation KRAS G12C inhibitor and is being studied across multiple KRAS G12C‑mutant cancers. The molecule had previously received Breakthrough Therapy designation for use with pembrolizumab (KEYTRUDA) in first‑line KRAS G12C NSCLC with PD‑L1 ≥50%.

Source: Lilly

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

1 October 2026
Lilly: Foundayo linked to reduced 10‑year predicted type 2 diabetes and cardiovascular risk

Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.

30 September 2026
Lilly: Lebrikizumab (EBGLYSS) meets primary endpoint in Phase 3b ADtouch for hand and foot atopic dermatitis

Rapid, significant relief in skin clearance, itch, pain and patient satisfaction versus placebo; consistent safety and fewer patients required rescue medication.

30 September 2026
Lilly's EloraTZP (eloralintide + tirzepatide) outperforms tirzepatide 15 mg in Phase 2b obesity and T2D trial

Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.

30 September 2026
Lilly’s Foundayo shows cardiovascular safety and durable A1C and weight benefits in ACHIEVE‑4

Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.

29 September 2026
Lilly: Zepbound (tirzepatide 10 mg, 15 mg) associated with greater weight loss than Wegovy HD (semaglutide 7.2 mg)

An indirect, covariate‑adjusted comparison of SURMOUNT‑1 and STEP UP data shows larger mean and categorical weight‑loss benefits with tirzepatide 10 mg and 15 mg at 72 weeks.